1 / 2

Enzo Biochem, Inc. v. Gen-Probe Inc. 323 F.3d 956 C.A.Fed. (N.Y.),2002.

Enzo Biochem, Inc. v. Gen-Probe Inc. 323 F.3d 956 C.A.Fed. (N.Y.),2002.

danno
Download Presentation

Enzo Biochem, Inc. v. Gen-Probe Inc. 323 F.3d 956 C.A.Fed. (N.Y.),2002.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Enzo Biochem, Inc. v. Gen-Probe Inc. 323 F.3d 956 C.A.Fed. (N.Y.),2002. (Rader, dissenting: at 981) In sum, the written description language has been in the statute since 1870, yet only since 1967 has case law separated it from enablement. The separation itself is not disruptive of the patent system, however, because the doctrine operated solely to police priority.

  2. Rader, cont’d • the aberrant form of WD requires far more specific disclosure than enablement. Because [it] . . . requires a far more demanding disclosure, defendants will have no need to invoke enablement, but will proceed directly to the more demanding . . . requirements. Thus, the new breed of WD [in] this case threatens to further disrupt the patent system by replacing enablement the statutory test for adequate disclosure.

More Related